MedTrace Logo

A Dose Finding Study of CpG in Patients With Chronic Lymphocytic Leukemia Who Have Been Previously Treated

NCT00233506 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2017-02-06

No results posted yet for this study

Summary

* CpG has the potential to stimulate the immune system
* this study will evaluate the safety of CpG given sub-q or IV
* purpose is to measure biological changes in CLL cells after receiving CpG

Conditions

Interventions

DRUG

CpG 7909

Sponsors & Collaborators

  • Mayo Clinic

    collaborator OTHER

  • Pfizer

    collaborator INDUSTRY

  • National Cancer Institute (NCI)

    collaborator NIH

  • University of Iowa

    lead OTHER

Principal Investigators

  • Brian Link, MD · UIHC

  • Clive Zent, M.D. · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-07-31
Primary Completion
2011-06-30
Completion
2011-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00233506 on ClinicalTrials.gov